NEMUS BIOSCIENCE INCORPORATED (OTCMKTS:NMUS) Has Decline in Shorts

July 18, 2017 - By Kurt Siggers

The stock of NEMUS BIOSCIENCE INCORPORATED (OTCMKTS:NMUS) registered a decrease of 11.78% in short interest. NMUS’s total short interest was 35,200 shares in July as published by FINRA. Its down 11.78% from 39,900 shares, reported previously. With 128,600 shares average volume, it will take short sellers 0 days to cover their NMUS’s short positions.

The stock increased 1.85% or $0.005 on July 17, reaching $0.275. About 35,980 shares traded. Nemus Bioscience Inc (OTCMKTS:NMUS) has 0.00% since July 18, 2016 and is . It has underperformed by 16.70% the S&P500.

Nemus Bioscience, Inc. is a biopharmaceutical company. The company has market cap of $7.94 million. The Firm is focused on the discovery, development and the commercialization of cannabinoid therapeutics through its partnership with the University of Mississippi . It currently has negative earnings. It is UM’s partner for the development and commercialization of drugs derived from cannabis extracts, or cannabinoids.

More notable recent Nemus Bioscience Inc (OTCMKTS:NMUS) news were published by: Seekingalpha.com which released: “NEMUS Bioscience: A Unique Approach To The 32 Million Rx US Glaucoma Market” on May 15, 2015, also Multiplesclerosisnewstoday.com with their article: “Leading Developer Of Cannabis-Based Therapeutics Nemus To Address MS, Other …” published on February 09, 2015, Streetinsider.com published: “Form 424B3 Nemus Bioscience, Inc.” on July 11, 2017. More interesting news about Nemus Bioscience Inc (OTCMKTS:NMUS) were released by: Seekingalpha.com and their article: “A Sit Down With Nemus Bioscience; Cannabinoids In Focus” published on February 01, 2017 as well as Seekingalpha.com‘s news article titled: “Is Nemus Bioscience An Investment Opportunity In The Cannabis Space?” with publication date: June 01, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.